Patents by Inventor Vivian M. Larson

Vivian M. Larson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody
    Patent number: 4761470
    Abstract: A synthetic peptide, containing the predicted amino acid residues 64 to 77 of the herpes simplex virus type 1 (HSV1) gB structural glycoprotein open reading frame, a synthetic subunit immunogen that stimulates an immune response against HSV1 and which, when prepared, and chemically-conjugated to a protein carrier molecule, and inoculated into test animals, gives rise to a specific anti-peptide IgG response, such that these anti-peptide antibodies react with a purified HSV-specific structural glycoprotein preparation and are capable of neutralizing the infectivity of HSV1.
    Type: Grant
    Filed: April 10, 1987
    Date of Patent: August 2, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Emilio A. Emini, Vivian M. Larson, Joshua S. Boger
  • Herpes subunit vaccine
    Patent number: 4452734
    Abstract: Herpes virus subunit antigens suitable for vaccine use are prepared by (1) treating virus-infected cells with a surfactant and varying concentrations of salt to extract and solubilize viral-directed glycoproteins, (2) fractionating the solubilized material by chromatographic procedures to enrich the viral-directed glycoproteins and to remove unwanted proteins and nucleic acids, and (3) optionally treating the subunit antigens with deoxyribonuclease and formaldehyde to assure safety.
    Type: Grant
    Filed: August 11, 1982
    Date of Patent: June 5, 1984
    Assignee: Merck & Co., Inc.
    Inventors: Vivian M. Larson, E. Dale Lehman
  • Herpes sub unit vaccine
    Patent number: 4374127
    Abstract: Herpes virus subunit antigens suitable for vaccine use are prepared by (1) treating virus-infected cells with a surfactant and varying concentrations of salt to extract and solubilize viral-directed glycoproteins, (2) fractionating the solubilized material by chromatographic procedures to enrich the viral-directed glycoproteins and to remove unwanted proteins and nucleic acids, and (3) optionally treating the subunit antigens with deoxyribonuclease and formaldehyde to assure safety.
    Type: Grant
    Filed: February 11, 1980
    Date of Patent: February 15, 1983
    Assignee: Merck & Co., Inc.
    Inventors: Vivian M. Larson, E. Dale Lehman